Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling by Janssen, E.J.H. et al.
Towards Rational Dosing Algorithms for Vancomycin in Neonates
and Infants Based on Population Pharmacokinetic Modeling
Esther J. H. Janssen,a Pyry A. J. Välitalo,a Karel Allegaert,b Roosmarijn F. W. de Cock,a Sinno H. P. Simons,c Catherine M. T. Sherwin,d
Johan W. Mouton,e Johannes N. van den Anker,f,g,h Catherijne A. J. Knibbea,i
Division of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlandsa; Neonatal Intensive Care Unit, University Hospital
Leuven, Leuven, Belgiumb; Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlandsc; Division of Clinical
Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USAd; Department of Medical Microbiology and Infectious Diseases,
Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlandse; Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC,
USAf; Department of Paediatric Pharmacology, University Children’s Hospital Basel, Basel, Switzerlandg; Intensive Care and Department of Pediatric Surgery, Erasmus MC-
Sophia Children’s Hospital, Rotterdam, the Netherlandsh; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, the Netherlandsi
Because of the recent awareness that vancomycin doses should aim tomeet a target area under the concentration-time curve
(AUC) instead of trough concentrations, more aggressive dosing regimens are warranted also in the pediatric population. In this
study, both neonatal and pediatric pharmacokinetic models for vancomycin were externally evaluated and subsequently used to
derive model-based dosing algorithms for neonates, infants, and children. For the external validation, predictions from previ-
ously published pharmacokinetic models were compared to new data. Simulations were performed in order to evaluate current
dosing regimens and to propose a model-based dosing algorithm. The AUC/MIC over 24 h (AUC24/MIC) was evaluated for all
investigated dosing schedules (target of>400), without any concentration exceeding 40 mg/liter. Both the neonatal and pediat-
ric models of vancomycin performed well in the external data sets, resulting in concentrations that were predicted correctly and
without bias. For neonates, a dosing algorithm based on body weight at birth and postnatal age is proposed, with daily doses di-
vided over three to four doses. For infants aged<1 year, doses between 32 and 60mg/kg/day over four doses are proposed, while
above 1 year of age, 60 mg/kg/day seems appropriate. As the time to reach steady-state concentrations varies from 155 h in pre-
term infants to 36 h in children aged>1 year, an initial loading dose is proposed. Based on the externally validated neonatal and
pediatric vancomycin models, novel dosing algorithms are proposed for neonates and children aged<1 year. For children aged 1
year and older, the currently advised maintenance dose of 60 mg/kg/day seems appropriate.
In the pediatric population, drugs are often administered in anoff-label or unlicensed manner (1). While pediatric dosing reg-
imens are mostly empirically derived using extrapolations based
on body weight (2, 3), it has been shown before that dosing in
children should be guided by the understanding of developmental
changes in the pharmacokinetic and/or pharmacodynamic rela-
tion of drugs (2, 4, 5).More specifically, translation of results from
pharmacokinetic modeling studies has been shown to result in
individualized dosing guidelines for many different drugs in pe-
diatric clinical practice (5–9).
The antibacterial agent vancomycin is commonly used to treat
infections caused by Gram-positive organisms, like methicillin-
resistant Staphylococcus aureus (MRSA) and amoxicillin-resistant
Enterococcus species, in both adults and pediatric patients (10). In
neonates, MRSA infection is relatively rare, and coagulase-nega-
tive staphylococci are the most commonly identified infectious
organisms necessitating vancomycin treatment (11, 12). For van-
comycin, it has been shown that bacterial killing of S. aureus is best
predicted by the area under the concentration-time curve over 24
h (AUC24) divided by theMIC for the infecting pathogen (AUC24/
MIC) (13–15). In adult patients, an AUC24/MIC of400 resulted
in a superior clinical and bacteriological response (16, 17). Be-
cause of the recent awareness that vancomycin doses should aim
to meet a target AUC or exposure instead of trough concentra-
tions (18), more aggressive dosing regimens are warranted also in
the pediatric population. Depending on the population and the
dosing frequency, target trough concentrations that can be used to
adjust the dose in an individual child in clinical practice (thera-
peutic drug monitoring [TDM]) can be derived that will lead to
the target AUC24 (19–21).
The exposure or AUC of vancomycin is dependent on the pri-
mary pharmacokinetic parameter total body clearance, which is
known to vary widely between infants and children of different
ages, especially in the heterogeneous group of preterm neonates
(19, 20, 22–36). Despite the large number of proposed vanco-
mycin dosing regimens currently available for neonates and
infants (10, 11, 37–41), studies reporting on the results of ther-
apeutic drug monitoring show that the target trough concen-
trations are difficult to attain in clinical practice (42–45). In
accordance with reported clinical practice in adults, continu-
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ous dosing has also been investigated in neonates, infants, and
children (31, 34, 46–49).
In previous reports, the developmental changes in vancomycin
pharmacokinetics have been characterized in both neonates and
children with normal renal function (defined as serum creatinine
two to three times higher than the age-related reference value) (22,
23). Both models were based on a very large number of patients
and internally validated (22, 23). In order to further investigate the
predictive performance of these models, an external validation
procedure with external data sets is needed (2–5). This external
validation is necessary to allow the use of the model for deriving
model-based dosing algorithms (3–5).
The aim of the current study is therefore to evaluate the pre-
dictive performance of the previously published neonatal and pe-
diatric pharmacokinetic models (22, 23) against an external van-
comycin data set containing preterm and term neonates and
infants. The model is then used to evaluate currently used dosing
regimens (37–40) in terms of target exposure. Based on the results
of these simulations, a model-based vancomycin dosing algo-
rithm for intermittent and continuous dosing will be derived that
can be used in prospective clinical trials to optimize vancomycin
treatment for neonates, infants, and children.
MATERIALS AND METHODS
Original models. Previously, population models both for neonates
(22) and for infants and children (23) have been developed in which
the developmental changes in vancomycin pharmacokinetics in neo-
nates and children were characterized. In the neonatal model (22),
birth body weight (bBW), postnatal age (PNA), and the coadministra-
tion of ibuprofen (with ibuprofen set at a value of 1 in the case of
ibuprofen coadministration and a value of 0 in the case of no coad-
ministration) were identified as covariates for clearance (equation 1)
while current body weight (cBW) was found as a covariate for the
central volume of distribution (equation 2). In these equations, Cli
represents the clearance in the ith individual, Vc,i is the central volume
of distribution in the ith individual, Qi is the intercompartmental
clearance in the ith individual, and Vp,i is the peripheral volume of
distribution in the ith individual.
Cliliters ⁄ h 0.053  bBW1, 750 g 1.34
 1 0.213 PNA2 days 0.838ibuprofen (1)
Vc,iliters 0.913  cBW1, 760 g0.919 (2)
Qiliters ⁄ h 0.904 Cli (3)
Vp,iliters Vc,i (4)
In the pediatric model (23), cBW was identified as a covariate for both
clearance (equation 5) and the central volume of distribution (equation 6).
Cli(liters ⁄ h) 0.39 cBW4 kg 2.23cBW0.065 (5)
Vc,i(liters ⁄ h) 2.22 cBW4 kg 1 (6)
Qiliters ⁄ h Cli (7)
Vp,i(liters) Vc,i (8)
External model validation and evaluation. Model validation using
external data sets was performed using NONMEM, version 7.3 (Icon De-
velopment Solutions, Hanover, MD). Tools like PsN, version 4.2.0 (Uni-
versity of Uppsala, Sweden) (50), and R, version 3.1.1 (R Foundation for
Statistical Computing, Vienna, Austria), were used to visualize data and
evaluate the model. External validation was performed with an external
data set containing TDM data which were not used for model develop-
ment (42). This external data set (42) consisted of both (pre)term neo-
nates and young infants (PNA up to 169 days; n 206). An overview of
the internal (model-building) (23, 24, 51) and external (42) data sets is
given in Table 1.
For the external validation, previously published pharmacokinetic
models (22, 23) were used to simulate each of the observations of the data
sets 1,000 times. Normalized prediction distribution errors (NPDE) (52,
53) were computed for each of the data sets. The NPDE were statistically
and visually evaluated for trends and bias. The NPDE were expected to
follow the normal distribution, N(0, 1).
Simulations. Concentration-time profiles were simulated in neo-
nates and children for different dosing regimens reported in the Dutch
Children’s Formulary (37), British National Formulary for Children
(BNFc) (38), the regimen proposed by the Infectious Diseases Society
of America (IDSA) (39), and the meningitis regimen of the NeoFax
manual (40) (see Table S1 in the supplemental material), using the
parameter estimates from the original models (22, 23). Simulations
were performed in six representative individuals (gestational ages
[GA] of 24, 34, and 40 weeks and a PNA of 2 weeks and infants/
children aged 6 months, 4, and 12 years (see Table S2). Infusion dura-
tion was 1 h (maximum, 10 mg/min), and treatment duration was 7
days. The AUC24 on day 7 was calculated noncompartmentally. For
TABLE 1 Overview of the internal data sets used to develop the original neonatal and pediatric models and of the external data set used for the
external validation of the original neonatal and pediatric modelsa
Parameter
Median value (range) for the parameter
Neonatal model Pediatric model
Internal data set External data set Internal data set External data set
No. of patients 273 191 429 206
Gestational age (weeks) 29 (23–34) 32 (24–41) NRb NR
Postmenstrual age (weeks) 30 (24–38) 34 (25–44) NR NR
Postnatal age (days) 14 (1–28) 8 days (1–31) 16 (1–6,205) 8 (1–169)
Current body weight (g) 1,170 (415–2,630) 1,780 (420–4,680) 1,800 (415–85,000) 1,870 (420–5,000)
Birth body weight (g) 1,140 (385–2,550) 1,775 (420–4,680) NR NR
Ibuprofen coadministration (no. [%]
of patients)
23 (8.4) 13 (6.8) NR NR
a For the neonatal model, see reference 22; for the pediatric model, see reference 23; for the internal data sets, see references 23, 24, and 51; for the external data set, see reference 42.
b NR, not relevant for the pediatric model.
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intermittent dosing, a peak concentration was simulated 1 h after the
end of infusion, and a trough concentration (Ctrough) was simulated
just before the next dose was given (10). For continuous dosing, a peak
concentration (1 h after the loading dose) and, every 12 h, a steady-
state concentration (Css) were simulated. Simulations were performed
excluding the interindividual and residual variability. Based on the
results, a model-based dosing algorithm was designed for neonates,
infants, and children without renal dysfunction (defined as serum cre-
atinine two to three times higher than the age-related reference value,
similar to that of the original models [22, 23]), aiming for a target
AUC24/MIC of 400 (17) without peak concentrations exceeding 40
mg/liter.
RESULTS
External validation of the neonatal model. In Fig. 1a and b, the
observed concentrations versus individual and population pre-
dicted concentrations are given for the neonatal model for the 191
neonates. Since the original model was built on vancomycin data
from neonates with GA of34 weeks, a distinction was made for
neonates with GA of 34 weeks or 34 weeks. Extrapolation to
neonates with GA of34 weeks was evaluated because the origi-
nal model used information on neonates with GA of 34 weeks
from neonates receiving amikacin (22). The results of these data,
together with the results of the NPDE analysis (mean, 0.0311;
variance, 1.051) (Fig. 1c), show that the neonatal model can pre-
dict the median concentrations accurately and without bias in
both preterm and term neonates. No clear trend was observed
between the NPDE versus time and NPDE versus predicted con-
centrations for neonates with GA of 34 weeks or 34 weeks
(Fig. 2), indicating that no time-dependent or concentration-de-
FIG 1 Results of the external validation of the models: observed versus individual predicted concentrations (a and d) and observed versus population predicted
concentrations (b and e) for the neonatal model (black dots, preterm neonates; gray dots, term neonates) and the pediatric model (black dots, postnatal age of
31 days; gray dots, postnatal age of30 days). The dotted lines represent the regression lines. The histograms (c and f) show the distributions of the normalized
prediction distribution errors (NPDE) for, respectively, the neonatal model and the pediatric model, with mean and variance of NPDE analysis. The gray dotted
boxes reflect the variance of the NPDE. *, variance is significantly different from 1 (P 0.01).
FIG 2 Results of the normalized prediction distribution error (NPDE) anal-
ysis of the neonatal model for individuals with GA of34 and of34 weeks
versus time and versus predicted concentration.
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pendent bias is present when predictions are made for new pa-
tients not included in the model-building data set.
External validation of the pediatric model. In Fig. 1d and e,
the observed concentrations versus individual and population
predicted concentrations are given for the pediatric model for the
206 patients. The results of these figures and the NPDE analysis
(mean,0.0536; variance, 1.215) (Fig. 1f) show that the pediatric
model can predict the median concentrations accurately.
Simulations of currently used dosing guidelines. Figure 3
shows concentration-time profiles during vancomycin treatment
for six representative individuals with current body weights vary-
ing between 0.640 kg and 45 kg following four different dosing
regimens currently proposed, i.e., Dutch Children’s Formulary
(37), BNFc (38), IDSA (39), and NeoFax (40). In neonates, the
dosing regimens as suggested by the Dutch Children’s Formulary
(37), BNFc (38), andNeoFax (40) generally led to anAUC24 below
400 mg · h/liter, except for some younger individuals (i.e., indi-
vidual 1, with a cBWof 640 g) for theDutch Children’s Formulary
(37) and individual 2 (cBW of 2.27 kg) for the BNFc regimen (38)
(Fig. 3). After treatment according to the regimen suggested by
IDSA (39), the AUC24 was above 400 mg · h/liter (Fig. 3). The
concentrations in the smallest individual (individual 1), treated
according to IDSA (39), exceeded 40 mg/liter (Fig. 3).
Individuals 4 to 6 treated according to the regimens in the
DutchChildren’s Formulary (37) and the BNFc (38) generally had
AUC24 values below 400 mg · h/liter at day 7 (Fig. 3). Dosing as
suggested by the IDSA (39) led to AUC24 values above 400 mg ·
h/liter for all individuals (Fig. 3).
Simulations to derive a model-based dosing regimen. Using
the externally validated neonatal and pediatric models, simula-
tions were performed aiming for individualized dosing guidelines
for neonates, infants, and children. Themodel-based dosing algo-
rithm is anticipated to result in an AUC24 at day 7 above 400 mg ·
h/liter. Table 2 shows these model-based dosing algorithms,
FIG 3 Model-based predicted concentration-time profiles for six individuals. The Dutch Children’s Formulary (37), British National Formulary for Children (BNFc)
(38), Infectious Diseases Society of America (IDSA) (39), and NeoFax (meningitis regimen) (40; see also Table S1 in the supplemental material) dosing guidelines and
model-based dosing algorithms (Table 2) were used. GA, gestational age; PNA, postnatal age; cBW, current body weight. The dotted lines indicate the target concen-
trations (10 to 15 mg/liter for trough concentrations upon intermittent dosing and 15 to 25 mg/liter for steady-state concentrations upon continuous dosing) and
concentrations abovewhich toxicitymight occur (40mg/liter). Concentrations outside the target andpeak concentrations above 40mg/liter are indicated by black dots.
AUC24h, calculated area under the concentration-time curve (mg · h/liter) on the seventh day of treatment.
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which are based on bBW, PNA, and the coadministration of ibu-
profen for neonates and on cBW for infants and children. To
calculate the dosages, cBW should be used for neonates, infants,
and children. Compared to the currently used dosing regimens
(37, 38, 40), the dosing frequency is increased to three to four
doses/day for neonates and young infants to prevent high peak
concentrations. For children aged 1 year and older, the dosing as
suggested by IDSA (39), 60 mg/kg/day in four doses, is main-
tained.
In neonates, time to steady state varied between approximately
155 h in a 1-week-old preterm neonate to 50 h in a 2-week-old
term neonate (Fig. 3). For the pediatric population (1 month of
age, irrespective of GA), the data in Fig. 3 show that the concen-
tration in young infants reaches steady state after approximately
45 h, which decreases to approximately 36 h in children aged 1
year and older. In order to reach steady state more rapidly, a load-
ing dose (Table 2) is proposed. After implementation of the load-
ing dose, the AUC24 on the first day of treatment will be above 400
mg · h/liter, which is not the case if no loading dose is given (Table
3). Similar results are obtained after implementation of a loading
dose for continuous dosing (results not shown).
DISCUSSION
In this study, both neonatal (22) and pediatric (23) vancomycin
models have been validated externally. Based on these models,
currently used dosing regimens have been evaluated uponwhich a
model-based dosing algorithmwas proposed for intermittent and
continuous administration of vancomycin in neonates and chil-
dren. An AUC24/MIC of over 400 was the aim. The results show
that for this AUC, the target Ctrough after intermittent dosing was
10 to 15mg/liter, and the targetCss after continuous dosingwas 15
to 25 mg/liter.
In order to facilitate the development of rational drug dos-
ing schemes in the pediatric population, new approaches are
TABLE 2 Proposed model-based vancomycin dosing algorithms for the neonatal and pediatric populationsa
Clinical characteristic Intermittent-dosing regimen Continuous-dosing regimen
PNAb
(days) bBW (g)c cBW (kg)d
Loading dose
(mg/kg)e,f
Maintenance dose
(mg/kg/day) (no.
of doses)f
AUC24
(mg · h/liter)g
Loading dose
(mg/kg)
Maintenance dose
(mg/kg/day)h
AUC24
(mg · h/liter)
0–7 700 16 15 (3) 264–301 10.5 25 440–502
700–1,000 21 (3) 332–450 25 395–536
1,000–1,500 27 (3) 349–490 27 349–484
1,500–2,500 30 (4) 339–530 30 339–530
2,500 36 (4) 354–482 36 354–482
8–14 700 20 21 (3) 331–590 10.5 25 394–703
700–1,000 27 (3) 341–475 32 404–563
1,000–1,500 36 (3) 390–610 36 390–610
1,500–2,500 40 (4) 380–504 40 380–504
2,500 48 (4) 390–633 48 390–633
14–28 700 23i 24 (3) 337–444 10.5 30 421–556
700–1,000 42 (3) 407–610 42 407–610
1,000–1,500 45 (3) 385–571 45 385–571
1,500–2,500 52 (4) 311–657 52 311–657
2,500 60 (4) 357–572 60 357–572
28 2.5 18 32 (4) 385–471 13 32 385–471
2.5–5.0 24 40 (4) 385–468 40 385–468
5.0–10.0 27 52 (4) 434–500 52 434–500
10.0 30 60 (4) 463–502 60 463–502
a This dosing algorithm (mg/kg current bodyweight) is based on a target AUC24/MIC of400.
b PNA, postnatal age.
c bBW: birth body weight.
d cBW, current body weight.
e The maximum loading dose is 1,200 mg.
f If ibuprofen is given and PNA is28 days, decrease the dose by 2 mg/kg/dose.
g AUC24 is the noncompartmental calculated area under the concentration-time curve over 24 h. Values are the expected daily AUC range for the different dosing groups.
h If ibuprofen is given and the PNA is28 days, decrease the maintenance dose by 6 mg/kg/day.
i The loading dose is 26 mg/kg if the PNA is 21 to 28 days.
TABLE 3 Expected AUC24 at 24h after start of treatment upon
intermittent dosing without and with the proposed loading dose
Individual
no. Agea
Expected AUC24
(mg · h/liter)b
Without
loading dose
With
loading dose
1 GA, 24 weeks; PNA, 14 days 233 411
2 GA, 34 weeks; PNA, 14 days 337 440
3 GA, 40 weeks; PNA, 14 days 362 436
4 PNA, 6 mo 344 457
5 PNA, 4 yr 358 466
6 PNA, 12 yr 351 433
a GA, gestational age; PNA, postnatal age.
b AUC24, calculated area under the concentration-time curve over 24 h.
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needed (2–5). At this moment, several pediatric pharmacoki-
netic models of vancomycin have been published (19–34, 36,
54–59), but only few individualized, model-based dosing algo-
rithms are available (25, 27, 30, 34, 57, 59). In clinical practice,
target concentrations and AUC24/MIC values are hard to
achieve (42–45, 60). Simulations based on two models (22, 23),
that are now validated internally and externally, showed, in-
deed, that adapted doses are needed, especially for neonates
and young infants. In the neonatal model (22), clearance is
dependent on birth body weight and postnatal age of the neo-
nates and the coadministration of ibuprofen. In the pediatric
model (23), the changes in clearance were described with a
body weight-dependent exponent model based on current
body weight. These clinical characteristics were taken into ac-
count in the developed model-based dosing algorithm (Table
2), and simulations showed that the target AUC24/MIC and
Ctrough were reached (Fig. 3). According to several currently
used dosing regimens (37, 38, 40), the daily dose should be
administered in two to three doses/day. For neonates and in-
fants, this was increased to three to four doses/day in the mod-
el-based dosing algorithm. Four doses/day are needed when
high dosages are needed to remain within the target for Ctrough;
otherwise these high dosages will increase the probability of
concentrations exceeding 40 mg/liter.
An AUC24/MIC of400 has been associated with clinical suc-
cess in adult patients withMRSA infections (16, 17).Whether this
target is directly applicable to children has to be determined (60).
For neonates, lower targets may suffice as most of the identified
infectious organisms are coagulase-negative staphylococci instead
of MRSA(11, 12). It has been reported that if the MIC is1 mg/
liter, 60 mg/kg/day seems necessary to reach an AUC24/MIC of
400 in children (20, 60–62).
In daily clinical practice the calculation of the AUC24 is not
reliable on the basis of the TDMsamples only. Therefore,Ctrough is
mainly used as a surrogate predictor of AUC24 although theCtrough
is dependent on the dosing interval. One can debate what the
proper Ctrough target range for neonates and infants is. IDSA rec-
ommends 15 to 20 mg/liter for severe infections after dosing two
to three daily for adults and four times daily for children (39).
Frymoyer et al. showed that a Ctrough of 7 to 11 mg/liter after
once/twice-daily dosing is appropriate for reaching an AUC24/
MIC of 400 in neonates (19). Other studies also showed that a
Ctrough of around 8mg/liter is appropriate for reaching theAUC24/
MIC target in children (20, 21). The currently proposed dosing
algorithm results in target trough concentrations between 10 and
15 mg/liter, with the data in Fig. 3 showing that the AUC24/MIC
target of400 is reached if the MIC is below 1 mg/liter.
Reaching the target AUC24/MIC in the first hours of treatment
is associatedwith better outcomes (16). Studies in both adults (63)
and neonates (34) show that higher concentrations are reached
when a loading dose is given than with conventional dosing. By
the implementation of a loading dose, steady-state concentrations
can be reached sooner, especially in neonates where the elimina-
tion half-life is much longer than that in children and adults. At
this moment, insufficient information is available regarding the
safety of the administration of a vancomycin loading dose. There-
fore, one could consider prolonging the infusion duration when a
loading dose is given to reduce the risk of possible infusion reac-
tions (17, 39). For intermittent dosing, the maximum loading
dose is 1,200 mg to limit the infusion time to 2 h, allowing for the
infusion line to be used for other drugs. The simulations of the
model-based dosing algorithms have shown that the target con-
centrations for both intermittent and continuous dosing were
reached within 24 h after administration of the loading dose (Ta-
ble 3). The proposed loading dose, especially the loading dose for
intermittent dosing, has to be tested in daily practice to confirm
the safety of these dosages. For continuous dosing, a reduction in
the loading dose compared to the loading dose suggested for in-
termittent dosing is proposed as the maintenance infusion starts
immediately after the loading dose.
Continuous infusion of vancomycin has several advantages
over intermittent infusion, for example, decreased pharmacoki-
netic variability and increased ease of TDM (18, 64). It has been
shown in adults that continuous administration decreases the risk
of nephrotoxicity compared to that with intermittent administra-
tion (64). However, although the number of neonates reaching
the target concentrations increasedwith continuous dosing, TDM
still seemed to be necessary (34). On the other hand, continuous
vancomycin dosing might be problematic in neonatal clinical
practice, especially in preterm neonates, because there may not be
intravenous access available for this continuous infusion.
The data used for the external validation of the neonatal model
consisted of both preterm and term neonates (42), and the model
proved to be good in terms of predictive performance for both
groups (Fig. 2). This is remarkable as the vancomycin data used
for building the neonatal model consisted of preterm neonates
only (GA up to 34 weeks) (Table 1) (51). However, for the vanco-
mycin model (22), a neonatal amikacin covariate model (6) was
used for extrapolation, for which data from both preterm and
term neonates were available (6). This amikacin covariate model
has been extrapolated not only to vancomycin but also to tobra-
mycin, gentamicin, and netilmicin (22). For all other antibiotics,
data were from both preterm and term neonates, and no predic-
tion bias in term neonates could be observed for any of these
antibiotics. Finally, an independent research group has success-
fully used the amikacin covariatemodel (6) to predict vancomycin
clearance in both term and preterm neonates (36). Therefore, our
conclusion that the model is valid for both preterm and term
neonates seems justified. As shown in Table 1, similar percentages
of the neonates included in model building (8.4%) and validation
(6.8%) received ibuprofen. In the data set used for developing the
amikacin covariate model, 13.5% received ibuprofen (6). There-
fore, the proposed dosing algorithm is valid for both neonates
receiving ibuprofen and those not receiving ibuprofen.
The original pediatric model was built using data from neo-
nates, infants, children, and adolescents (Table 1). Thismodel was
developed to define a function to describe the maturation in glo-
merular filtration rate (GFR) (23). AdultGFR levels, expressed per
unit of body surface area, are reached at approximately 6 to 12
months of age (65–68). External validation of this model was lim-
ited to neonates and young infants up to 6 months of age since no
additional data were available. As the GFR approaches adult val-
ues at 6 to 12 months, the period where most developmental
changes happen is covered by this external validation. For older
infants and children, an additional external validation procedure
should be performed. Based on these results, the proposed dosing
algorithm should be adapted when necessary, with particular fo-
cus on infants older than 169 days.
In conclusion, both the neonatal and pediatric models could
describe the data in the external data set well. This study shows
Janssen et al.
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that with currently used dosing regimens, the target AUC24/MIC
and trough concentrations are hardly reached in neonates and
young infants, whereas the model-based dosing algorithm results
in the target exposure after both intermittent and continuous dos-
ing. For children aged 1 year and older, the currently used dose of
60 mg/kg/day seems appropriate. In order to reach an AUC24/
MIC of400 on the first day of treatment, a loading dose should
be administered. A prospective clinical study is warranted in order
to validate the model-based dosing algorithm.
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